Skip to content
Screener

Dianthus Therapeutics DNTH Price / sales

Price / sales at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
6.2×+2.2×
Amgen logo
AmgenAMGN
5.1×+0.9×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6.9×+1.8×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
662.8×+646×
TG Therapeutics logo
TG TherapeuticsTGTX
10.5×-2.5×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
1,993×+1,970×

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.09B+902%
Enterprise value$5.47B+817%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

market cap/total revenue=509×

Based on the most recent quarter.

The source filing: Dianthus Therapeutics’s 10-Q, filed November 5, 2025. Open the filing →

Filed
Nov 5, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0001193125-25-266920

FAQ

What is Dianthus Therapeutics's price / sales?
Dianthus Therapeutics (DNTH) reported price / sales of 509× in Q3 2025.
How has Dianthus Therapeutics's price / sales changed year-over-year?
Dianthus Therapeutics's price / sales increased by 191.4% year-over-year, from 174.7× to 509×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Ask your AI about Dianthus Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude